Clearmind Medicine Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Clearmind Medicine Inc. is a clinical-stage pharmaceutical company that develops novel psychedelic-derived medicines aimed at treating widespread and under-served health problems. The company’s core product offerings include psychedelic-based therapeutics targeting alcohol use disorders, binge drinking, eating disorders, weight loss, obesity, metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment-resistant depression. Its key products under development are the MEAI compound for treating alcohol use disorder, obesity, and metabolic disorders, including an alcohol substitute consumer product, and CM-CMND-001, currently in Phase I/IIa clinical trials for alcohol use disorder treatment. The company also explores combination treatments for obesity and metabolic syndrome through collaborations. Recent major changes include a strategic partnership with Dr. Glitter Pty Ltd to co-develop and commercialize an MEAI-based alcohol substitute using Dr. Glitter’s ActivCrystal™ technology, an innovative oral delivery format that enables flexible consumption by sprinkling the product onto food or beverages. This partnership aims to provide a safer alternative to traditional alcohol consumption, addressing alcohol misuse and related health risks. Additionally, Clearmind obtained final regulatory approval from Hadassah Medical Center in Jerusalem to expand its Phase 1/2a clinical trial for CMND-100, furthering its multinational studies that include leading medical centers such as Yale and Johns Hopkins. The company has also engaged JS First Sdn. Bhd to source global manufacturers and distributors, supporting its international expansion plans. Furthermore, Clearmind secured $10 million in a securities purchase agreement to advance strategic opportunities and has recently filed for patents related to novel non-hallucinogenic neuroplastogen treatments for depression. Operating primarily in the biotechnology and healthcare sectors, Clearmind Medicine targets mental health and metabolic disease markets worldwide. Founded in 2017, the company is headquartered in Vancouver, Canada. It maintains a collaborative research relationship with Yissum Research Development Company of the Hebrew University of Jerusalem for developing and commercializing compounds for PTSD and other conditions. The company was formerly known as Cyntar Ventures Inc. until its name change to Clearmind Medicine Inc. in March 2021. Clearmind’s broad clinical pipeline and strategic alliances position it as an innovator in psychedelic medicine development with a focus on transforming treatment options for alcohol-related and mental health disorders.
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
Clearmind Medicine Announces 1-for-10 Reverse Share Split
Clearmind Medicine Announces 1-for-10 Reverse Share Split
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial